臨床試驗

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

NCT：NCT02880618 · RECRUITING

NCT IDNCT02880618

狀態RECRUITING

開始日期2016-12-13

SponsorCVRx, Inc. (INDUSTRY)

First posted2016-08-26

Last updated2026-09-11

簡要摘要

The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。